Immunoassay for Colistin Monitoring in Critically Ill Patients Receiving Colistin Methanesulfonate Therapy
Rattachement africain : gb, ru, cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background/Objectives: Colistin (COL), administered as a prodrug colistimethate sodium (CMS), is commonly used to treat infections caused by multidrug-resistant Gram-negative bacteria in critically ill patients. Given high CMS instability, very complex and variable pharmacokinetics (PK) and high incidence of toxicity, therapeutic drug monitoring (TDM) of active COL might play an important role. This study aimed to develop and validate an accessible immunoassay-based approach for COL monitoring in human serum. Methods: A direct competitive enzyme-linked immunosorbent assay (dcELISA) was developed using polyclonal (pAb) anti-polymyxin antibody alongside a polymyxin B–horseradish peroxidase conjugate. CMS conversion to COL along with serum deproteinization was achieved using 5% trichloroacetic acid (TCA) treatment at 37 °C. Assay accuracy and precision were assessed by spike-and-recovery experiments in healthy volunteer serum. The assay was applied to serum samples from critically ill patients with burns or pneumonia receiving CMS therapy. The reliability of the measurements was confirmed by parallel dcELISA based on a reference monoclonal antibody (mAb) against fragmented polymyxin molecule. Results: Both ELISA formats demonstrated high sensitivity, with limits of detection of 0.053 ng/mL (pAb) and 0.047 ng/mL (mAb). TCA treatment achieved maximal CMS hydrolysis under tested conditions within one hour. Clinical sample analysis showed excellent agreement between the two assays (R2 = 0.996), with Bland–Altman analysis revealing a minimal bias of 3.7%. Exploratory PK analysis in burn patients demonstrated increased total drug volume of distribution (45.7–64.9 L) and clearance (8.3–16.3 L/h). Conclusions: This is the first report of ELISA for COL TDM in critically ill patients. The method offers acceptable analytical performance and practical simplicity, with potential to broaden TDM access beyond specialist centers.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Immunoassay for Colistin Monitoring in Critically Ill Patients Receiving Colistin Methanesulfonate Therapy
- Date Crossref
- 01/06/2026
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University College Hospital pays non établi dans la noticeÉtablissement de santé
-
University College London pays non établi dans la noticeUniversité ou école supérieure
-
Middlesex University London pays non établi dans la noticeUniversité ou école supérieure
-
Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences pays non établi dans la noticeStructure de recherche
-
Lomonosov Moscow State University pays non établi dans la noticeUniversité ou école supérieure
-
Federal State Budgetary Institution "Federal Center For Cardiovascular Surgery" Ministry of Health of The Russian Federation Federal Center for Treatment and Rehabilitation pays non établi dans la noticeÉtablissement de santé
-
China Agricultural University pays non établi dans la noticeUniversité ou école supérieure
-
All-Russian Research Institute for Animal Health pays non établi dans la noticeStructure de recherche
-
University College of London Hospital Department of Critical Care pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Science and Technology pays non établi dans la noticeUniversité ou école supérieure
-
I. Mechnikov Research Institute for Vaccines and Sera Department of Immunology pays non établi dans la noticeStructure de recherche
-
Faculty of Medicine pays non établi dans la noticeUniversité ou école supérieure
University College Hospital, University College London et Middlesex University London, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.